今日新闻精选

[6.3] 美国承诺向乌克兰提供十年军事援助 — kcra.com(+378)

The U.S. and Ukraine have finalized a ten-year agreement guaranteeing continued military aid to Ukraine amidst the ongoing war.

美国和乌克兰已签署一项为期十年的协议，保证在持续战争期间继续向乌克兰提供军事援助。

The deal grants the U.S. access to critical minerals and removes a barrier to Ukraine’s potential EU membership. The White House views the agreement as a demonstration of its commitment to Ukraine’s long-term stability.

该协议使美国能够获取关键矿物资源，并消除了乌克兰潜在加入欧盟的一个障碍。白宫认为该协议体现了其对乌克兰长期稳定的承诺。

This agreement comes as peace negotiations between Russia and Ukraine face challenges, with Russia proposing a short-term truce and expressing reluctance for a quick resolution.

该协议签署之际，俄乌和平谈判正面临挑战，俄罗斯提议短期停火，并表示不愿快速解决问题。

[6.5] 全球核聚变项目取得里程碑进展：建成世界最强磁体 — reuters.com(+2)

A global nuclear fusion project is set to assemble the world’s most powerful magnet, a crucial step toward generating clean energy through atomic fusion.

一个全球核聚变项目即将组装世界上最强磁体，这是通过原子聚变产生清洁能源的关键一步。

The International Thermonuclear Experimental Reactor (ITER) project, involving over 30 countries, completed the final component of its magnetic system, the central solenoid, after delays. This magnet will confine super-hot plasma, enabling fusion reactions.

由30多个国家参与的国际热核聚变实验堆(ITER)项目在经历延误后，完成了其磁系统最后一个部件——中心螺线管的建造。该磁体将约束超高温等离子体，实现聚变反应。

The project, based in France, aims to start generating plasma in 2033, despite past setbacks. While fusion investment grows, ITER’s director remains skeptical of rapid commercialization by private ventures.

这个位于法国的项目目标是在2033年开始产生等离子体，尽管过去遭遇挫折。虽然聚变投资在增长，但ITER负责人仍对私营企业快速商业化持怀疑态度。

[5.9] 研究显示：免疫疗法药物可消除某些早期癌症肿瘤 — abcnews.go.com(+3)

A new immunotherapy drug, dostarlimab, has shown the potential to eliminate tumors in some early-stage cancer patients, potentially allowing them to avoid surgery.

一种新型免疫疗法药物dostarlimab已显示出消除某些早期癌症患者肿瘤的潜力，可能使他们免于手术。

In a study, 82 out of 103 participants responded so well to dostarlimab that they no longer needed surgery. The study focused on patients with a specific genetic mutation, and all 49 rectal cancer patients avoided surgery after treatment.

在一项研究中，103名参与者中有82人对dostarlimab反应良好，不再需要手术。该研究针对具有特定基因突变的患者，所有49名直肠癌患者在治疗后都避免了手术。

While promising, the study was conducted at a single hospital and included a select group of patients. Researchers are working to expand the study and explore combining immunotherapy with other approaches.

尽管前景看好，但该研究是在单一医院进行的，且只包括特定患者群体。研究人员正在努力扩大研究范围，探索将免疫疗法与其他方法相结合。

其他重要新闻(显著性评分超过5.5)

[5.6] 微软CEO纳德拉称公司30%代码现由AI生成 — [businesstoday.in](https://www.businesstoday.in/tech

点击阅读原文《US guarantees Ukraine military aid for ten years + 2 more stories》